Clinical Trial

Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer

Completed
View on ClinicalTrials.gov →
Summary
This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer. QTI is a single 3D ultrasound test intended to be used as an initial evaluation method for asymptomatic women identified with above-average risk for developing breast cancer. Using QTI may be an effective supplemental screening tool, compared to MRI for patients with a high lifetime risk of breast cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-10-10; most recent amendment 2026-05-22.
Status change: Recruiting → Completed 2025-12-04
Trial Details
NCT Number NCT07216274
Lead Sponsor Mayo Clinic
Conditions Breast Carcinoma
Enrollment 26 participants
Start Date 2025-07-31
Primary Completion 2025-10-20 (estimated)
Study Completion 2025-10-20 (estimated)
Updated on ClinicalTrials.gov 2026-05-27